Seven Eight Capital, LP Bluebird Bio, Inc. Transaction History

Seven Eight Capital, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$18.04 - $22.09 $259,884 - $318,228	-14,406 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$27.5 - $37.92 $255,750 - $352,656	9,300 Added 182.14%	14,406 $623,000
Q3 2020 Nov 16, 2020	BUY	$34.44 - $43.75 $175,850 - $223,387	5,106 New	5,106 $275,000
Q4 2017 Feb 12, 2018	SELL	$81.25 - $130.7 $1.02 Million - $1.64 Million	-12,511 Closed	0 $0
Q3 2017 Oct 16, 2017	BUY	$57.74 - $91.42 $722,385 - $1.14 Million	12,511	12,511 $1.72 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.